We are pleased to announce our newest paper in Cancers MDPI is now published online!
This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01) in ovarian cancer therapy, and shows how selective antagonization of TSP-1:CD47 axis is a new powerful way of activating anti-tumor immunity.
We believe our innovative technology to be a safer and effective approach with the potential to treat multiple indications of solid tumors.
Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet medical needs.
Beyond our oncology expertise, our innovative technological approach interfering with TSP-1/CD47 signaling may improve the lives of a large fraction of the (aging) population, such as people suffering from cardiovascular diseases.
Check out out pioneering results newly published in ATVB An American Heart Association Journal establishing Apmonia Tx’ asset as a new strategy of high therapeutic interest in controlling platelet activation and related thrombotic disorders, while being associated with a favorable safety profile and low bleeding risk.